Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
Authors
Keywords
-
Journal
ANNALS OF SAUDI MEDICINE
Volume 43, Issue 5, Pages 308-314
Publisher
King Faisal Specialist Hospital and Research Centre
Online
2023-10-09
DOI
10.5144/0256-4947.2023.308
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
- (2022) Sarah Blach et al. Lancet Gastroenterology & Hepatology
- National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents
- (2022) Maria Lúcia Gomes Ferraz et al. Brazilian Journal of Infectious Diseases
- An update on direct antiviral agents for the treatment of hepatitis C
- (2021) Carol Stanciu et al. EXPERT OPINION ON PHARMACOTHERAPY
- Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
- (2021) Sona Frankova et al. Harm Reduction Journal
- Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis
- (2020) Yukihisa Yuri et al. Journal of Clinical Medicine
- Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
- (2020) Eric Lawitz et al. Lancet Gastroenterology & Hepatology
- Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil
- (2020) Mario Peribañez-Gonzalez et al. Annals of Hepatology
- Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease
- (2020) Sherief Abd-Elsalam et al. MEDICINE
- Low adherence achieves high HCV cure rates among people who inject drugs treated with direct-acting antiviral agents.
- (2020) Brianna L Norton et al. Open Forum Infectious Diseases
- Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi
- (2019) Peter Ferenci et al. JOURNAL OF VIRAL HEPATITIS
- Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients
- (2019) Nicole Loo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)
- (2018) Vasily Isakov et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
- (2018) Gamal Shiha et al. GUT
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
- (2018) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
- (2017) Paul Y. Kwo et al. JOURNAL OF HEPATOLOGY
- Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
- (2017) Xavier Forns et al. LANCET INFECTIOUS DISEASES
- Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study
- (2015) N. Tozun et al. CLINICAL MICROBIOLOGY AND INFECTION
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease
- (2013) Yi-Chun Chen et al. KIDNEY INTERNATIONAL
- Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis
- (2011) Ross J. Harris et al. EUROPEAN JOURNAL OF PUBLIC HEALTH
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More